CFO’s $2.00 Insider Buy at Privia Health: 10‑b5‑1 Plan Signals Confidence Amid High Valuation

Insider Buying Spree at Privia Health Group

On February 26 2026, Mountcastle David, Privia Health Group’s EVP and Chief Financial Officer, executed a Rule 10b5‑1‑planned purchase of 5,361 shares at $2.00 per share—an aggressive buy in a stock that recently closed at $21.53. The transaction, disclosed in a Form 4 filing, inflates David’s holdings to 178,270 shares, roughly 6.7 % of outstanding shares. While the purchase price is markedly below the current market level, the plan’s existence suggests a long‑term confidence in the company’s trajectory.

Why the Timing Matters

The buy arrives amid a period of heightened social‑media chatter—an 82.49 % buzz spike—and a modest 0.12 % uptick in the share price. Historically, David has executed a mix of buys and sells in a 10b5‑1 framework: in December 2025 he bought 23,887 shares at $2.00 and sold 23,887 at $25.03; in April 2025 he sold 5,630 shares at $22.38. The pattern shows disciplined, schedule‑based trading rather than opportunistic trades, mitigating “insider‑confidence” concerns that could trigger a market‑reaction alarm.

Investor Takeaway

For investors, David’s recent buy may signal management’s belief that the stock is undervalued relative to its growth prospects. Privia’s valuation multiples—P/E 155.46, P/B 3.81—indicate a premium pricing based on future earnings expectations. A 10b5‑1 buy at $2.00 demonstrates that insiders are willing to pay a fraction of the current price, implying confidence in a price rebound. However, the company’s earnings volatility and high valuation mean that a cautious approach remains prudent. A strategic investor might view the buy as a green light to increase exposure, while a risk‑averse investor could monitor upcoming quarterly results before committing.

Mountcastle David: The Insider Profile

David has maintained a consistent trading cadence through the 10b5‑1 plan, balancing purchases and divestitures. Over the past year, he has accumulated over 180,000 shares while periodically selling large blocks at near‑market prices (e.g., 23,887 shares at $25.03 in December 2025). He has also sold numerous vested options—totaling more than 50,000 shares—at zero cost, effectively converting option value into cash. This behavior underscores a strategy of leveraging options to fund purchases, a common practice among CFOs who manage liquidity while signaling long‑term faith in the firm. His transaction history suggests a pragmatic approach: buying low, selling high, and using options as a financial tool rather than speculation.

Implications for Privia’s Future

The infusion of capital from David’s purchases, coupled with his historical option sales, could provide the company with a modest liquidity buffer—valuable for pursuing platform expansion or strategic acquisitions. Moreover, his buying activity may influence sentiment, as insiders often serve as confidence signals in the healthcare‑tech space, where product adoption and regulatory hurdles can cause volatility. If the stock continues to rally toward its 52‑week high of $26.51, David’s stake could translate into significant upside for shareholders.

In summary, Mountcastle David’s 10b5‑1 purchase at $2.00 per share signals insider conviction while maintaining transparency and regulatory compliance. Investors should weigh this confidence against the company’s high valuation and sectoral risks, using the buy as a data point in a broader assessment of Privia Health Group’s growth prospects.